StockDrifts LogoStockDrifts

Samchundang Pharmaceutical 000250

Company
삼천당제약Samchundang Pharmaceutical
Insiders
0
Buys
0
Total Value
—
Avg Return
—
Last Filing
2025-07-24

Samchundang Pharmaceutical (000250) has 0 disclosed insider purchases and 0 disclosed disposals on record, filed by 0 distinct insiders. The earliest filing StockDrifts holds for Samchundang Pharmaceutical is dated 2025-07-24; the most recent is 2025-07-24.

Price & insider activity (12 months)

Recent insider trades

DateTypeSourceInsiderPositionSharesPrice at filingReturnValue
2025-07-24SELL증여
윤대인
Daein Yoon
Chairman-799.7K₩225,500-173.2%₩180.3B ($125.2M)
2025-07-24SELL증여
윤대인
Daein Yoon
Chairman-799.7K₩225,500-173.2%₩180.3B ($125.2M)
2025-07-24BUY수증
전인석
Jeon In-seok
CEO799.7K₩225,500+173.2%₩180.3B ($125.2M)

Frequently asked questions

Who has been buying Samchundang Pharmaceutical stock?
0 distinct insiders have filed 0 disclosed insider purchases in Samchundang Pharmaceutical (000250), most recently on 2025-07-24. Each filer, their role, the number of shares and the price at filing are listed in the table on this page.
How many insider filings does Samchundang Pharmaceutical have?
Samchundang Pharmaceutical has 0 buy-side and 0 sell-side disclosures on record, spanning 2025-07-24 to 2025-07-24.
Do insider buys in Korean stocks predict returns?
Not uniformly. StockDrifts analysed 170,720 share-count changes across 56,930 Korean regulatory filings using cross-sectional alpha at fixed forward horizons, and found returns concentrated in particular signal tiers rather than in insider buying generally.

More on this data

Every trade listed above comes from an official regulatory disclosure. For how StockDrifts scores these disclosures, see the Korea insider signal tier research, or browse every Korean stock we track.